Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Am J Obstet Gynecol. 2010 Sep 25;203(6):582.e1–582.e7. doi: 10.1016/j.ajog.2010.07.041

Figure 2.

Figure 2

Representative effect of low doses of interleukin-2 (IL-2) in combination with MT201 (5 μg/ml) on ADCC against OSPC-ARK-1 primary cell line (Effectors to target ratio 25:1). PBL from healthy donors were incubated for 4 hours in the presence of 100 IU/ml of IL-2. MT201-mediated ADCC was significantly increased in the presence of low doses of IL-2. No significant increase in cytotoxicity was detected after 4-h IL-2 treatment in the absence of MT201 or in the presence of the rituximab isotype control mAb.